Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 15;10(1):25-30.
eCollection 2022.

Evaluating the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the chordee patients with Peyronie disease

Mohammad Hatampour  1 , Karim Sohrabi  2 , Hamid Mazdak  3 , Keyvan Ghadimi  1 , Hanieh Salehi  1 , Reza Kazemi  3
Affiliations

Evaluating the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the chordee patients with Peyronie disease

Mohammad Hatampour et al. Am J Clin Exp Urol. .

Abstract

Background: Some studies demonstrated the effect of the combination of modalities in Peyronie's disease (PD) therapy; however, there is no comprehensive study for evaluation of dexamethasone and phosphodiesterase type 5 (PDE5) inhibitors such as tadalafil in the treatment of PD, so the study aimed to evaluate the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the patients with PD.

Materials and methods: This double-blinded randomized, controlled trial was conducted on the patients with PD referred to Alzahra and Khorshid hospitals, Isfahan, Iran. Then the patients were randomly divided into two groups as intervention and control groups. In the intervention group, tadalafil (5 mg PO) was administered once daily for 12 weeks and dexamethasone (8 mg) was injected once a week for 12 weeks. In the control group, the verapamil (5 mg: 2 cc) was injected once a week for 12 weeks. Before and after 12 weeks, an ultrasound was performed to assess the size, number and location of the plaque. The degree of penile curvature from the midline, dorsal and lateral curvature was also determined.

Results: The means of penis curvature in the intervention and control groups before therapy were 34.09±7.05˚ and 31.09±7.06˚, respectively (P=0.097) and also after therapy were 27.3±7.79˚ and 24.6±6.64˚, respectively (P=0.13). The means of plaque count in the intervention and control groups before treatment were 2.0±1.03 and 1.96±1.06, respectively (P=0.9) and after treatment were 1.22±0.71 and 1.40±0.79, respectively (P=0.34). The means of plaque size in the intervention and control groups were 12.31±4.9 cm and 12.45±4.12 cm, respectively (P=0.9) and after intervention 7.8±3.08 and 9.03±3.46 cm, respectively (P=0.15).

Conclusion: According to these findings, there was no significant difference between intervention and control groups regarding the degree of penis curvature, and the count and size of the plaque. Therefore, it seems that tadalafil therapy with dexamethasone did not improve PD compared to verapamil.

Keywords: Dexamethasone; Peyronie’s disease; tadalafil.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Consort flowchart of patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R, Hellstrom W. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171:2350–2353. - PubMed
    1. Bella AJ, Perelman MA, Brant WO, Lue TF. Continuing medical education: Peyronie’s disease (CME) J Sex Med. 2007;4:1527–1538. - PubMed
    1. Taylor FL, Levine LA. Peyronie’s disease. Urol Clin North Am. 2007;34:517–534. - PubMed
    1. Gokce A, Wang JC, Powers MK, Hellstrom WJ. Current and emerging treatment options for Peyronie’s disease. Res Rep Urol. 2013;5:17–27. - PMC - PubMed
    1. Dell’Atti L. Tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in Peyronie’s disease. Urol Ann. 2015;7:345–359. - PMC - PubMed

LinkOut - more resources